Medical Management of Benign Prostatic Hyperplasia
March 2024
in “
Cleveland Clinic journal of medicine
”
TLDR Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
Medical management of benign prostatic hyperplasia (BPH) has advanced, with alpha-blockers and 5-alpha reductase inhibitors remaining primary treatments. New evidence supports the use of phosphodiesterase-5 inhibitors and beta-3 agonists for additional symptom relief. This review focuses on the indications, benefits, and side effects of these pharmacotherapies, while surgical treatments are discussed elsewhere.
